A new study indicates that more patients diagnosed with colorectal and endometrial cancers could benefit from immunotherapy. The DNA Mismatch Repair Deficiency (MMR-D) is an important marker that should guide treatment decisions. Traditional immunohistochemistry (IHC) and next-generation sequencing (NGS) are the two lab testing methods that were compared, finding that NGS offers a more accurate assessment of MMR status. It was discovered that 1% of patients with colorectal cancer and 6% with endometrial cancer are mismatch repair-deficient but are missed by IHC, still, they can be detected by NGS. Researchers estimate that implementing NGS alongside IHC could identify an additional 6,000 patients in the United States annually who could benefit from immunotherapy.
Source link
New study expands immunotherapy eligibility for colorectal and endometrial cancer patients
